OCTOPLUS SUCCESSFULLY RAISES € 6 MILLION

Leiden, the Netherlands, 20 February 2009 – OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces today that it has successfully raised € 6.0 million through a private placement with institutional investors of 8.0 million new ordinary shares (the “Offering”).

Subject to certain conditions that are standard for this type of transaction, the new shares are expected to be issued and paid for on 24 February 2009. The total number of outstanding shares immediately following the settlement of the Offering is expected to be approximately 30.2 million. This number includes the 6.0 million new ordinary shares created through the conversion of the principal amount as well as the accrued but unpaid interest thereon of the convertible loans held by SR One and Life Sciences Partners. These two parties each granted OctoPlus a convertible loan of € 2 million in 2008.

The shares issued pursuant to the Offering will be admitted to listing and trading on Euronext Amsterdam by NYSE Euronext (“Euronext Amsterdam”) as soon as reasonably possible, provided that the request thereto to Euronext Amsterdam will in any case be made by the Company within 90 days after the closing date of the Offering on the basis of a listing prospectus which will be prepared by the Company and which requires approval from the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) in accordance with the rules of the Act on the Financial Supervision (Wet op het financieel toezicht). Until the shares issued pursuant to the Offering are admitted to listing and trading on Euronext Amsterdam, they will not be tradable via Euronext Amsterdam.

Kempen & Co acted as placement agent and financial advisor to OctoPlus in relation to the Offering.

Simon Sturge, CEO of OctoPlus, comments: “I am delighted to see such significant support for the Company’s new strategy from both new and existing institutional investors, in particular Signet Healthcare Partners, whom I look forward to welcoming to OctoPlus’ Board of Supervisory Directors.”